Opiate replacement therapy in France: Assessment of the public policies;Les traitements de substitution aux opiacés : bilan des politiques publiques

Annales Pharmaceutiques Francaises

Volumn 67, Issue 5, 2009, Pages 299-303

  Chast, F ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; OPIATE;

COMORBIDITY; DRUG OVERDOSE; EDITORIAL; FRANCE; HEALTH CARE POLICY; HEALTH PRACTITIONER; HUMAN; MONOTHERAPY; OPIATE ADDICTION; PATIENT SATISFACTION; PRESCRIPTION; PUBLIC HEALTH SERVICE; SOCIAL PSYCHIATRY; SUBSTITUTION THERAPY; TREATMENT INDICATION; TREATMENT PLANNING;

BUPRENORPHINE; FRANCE; HEALTH POLICY; HUMANS; LEGISLATION, MEDICAL; MENTAL DISORDERS; METHADONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 68849108346     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2009.06.006     Document Type: Editorial

References (7)

1. Henrion R. Efficacité des mesures prises en France pour réduire les effets de la toxicomanie à l'héroïne par voie veineuse. Bull Acad Natl Med 181 6 (1997) 1177-1185 [discussion 1186-1189]
2. o 29 du 31.03.1995.
3. Fatseas M., and Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 9 5 (2007) 358-364
4. ® en médecine de ville (SPESUB) ; Revue d'épidémiologie et de santé publique (2000);48(4):363.
5. Obadia Y., Perrin V., Feroni I., Vlahov D., and Moatti J.P. Injecting misuse of buprenorphine among French drug users. Addiction 96 2 (2001) 267-272
6. Mégarbane B., Hreiche R., Pirnay S., Marie N., and Baud F.J. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 25 2 (2006) 79-85
7. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend., Available online 13 May 2009.